Literature DB >> 16316356

Health-related quality of life and estimates of utility in chronic kidney disease.

Irina Gorodetskaya1, Stefanos Zenios, Charles E McCulloch, Alan Bostrom, Chi-Yuan Hsu, Andrew B Bindman, Alan S Go, Glenn M Chertow.   

Abstract

BACKGROUND: Health-related quality of life and estimates of utility have been carefully evaluated in persons with end-stage renal disease. Fewer studies have examined these parameters in persons with chronic kidney disease (CKD).
METHODS: To determine the relations among kidney function, health-related quality of life, and estimates of utility, we administered the Kidney Disease Quality of Life Short Form 36 (KDQOL-36), Health Utilities Index (HUI)-3, and Time Trade-off (TTO) questionnaires to 205 persons with CKD. Persons with CKD stages 4 and 5 (estimated GFR <30 mL/min/1.73 m2, N= 115) were tested two to eight times over the subsequent two years. The relations among estimated glomerular filtration rate (eGFR), and changes in health-related quality of life and utility over time were estimated using mixed effect regression models. Models were adjusted for age, sex, race, and diabetes.
RESULTS: Mean scores on the KDQOL-36 generic components, HUI-3, and TTO suggested considerable loss of function and well-being in CKD relative to population norms. On cross-sectional analysis, lower levels of kidney function were associated with significantly lower scores on the SF-12 Physical Health Composite (P= 0.002), the Burden of Kidney Disease subscale (P < 0.0001), and the Effects of Kidney Disease subscale (P < 0.0001) of the KDQOL-36trade mark. Kidney function was significantly associated with the TTO (P= 0.008) and global HUI-3 utility (P= 0.016) although these associations were attenuated after adjustment for diabetes. A decline in eGFR was associated with a significant increase in the reported Burden of Kidney Disease (5.0 point change per year per mL/min/1.73 m2 decline in eGFR) and with marginally significant changes in the Dexterity and Pain attributes of the HUI-3. Mean HUI-3 scores for persons with CKD stages 4 and 5, absent dialysis, were in the range previously reported for persons with stroke and severe peripheral vascular disease.
CONCLUSION: Health-related quality of life and estimates of utility are distressingly low in persons with CKD. Self-reported outcomes should be considered when evaluating health policy decisions that affect this population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16316356     DOI: 10.1111/j.1523-1755.2005.00752.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  107 in total

1.  Adding specialized clinics for remote-dwellers with chronic kidney disease: a cost-utility analysis.

Authors:  Natasha Wiebe; Scott W Klarenbach; Betty Chui; Bharati Ayyalasomayajula; Brenda R Hemmelgarn; Kailash Jindal; Braden Manns; Marcello Tonelli
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

2.  Estimating utilities for chronic kidney disease, using SF-36 and SF-12-based measures: challenges in a population of veterans with diabetes.

Authors:  Mangala Rajan; Kuan-Chi Lai; Chin-Lin Tseng; Shirley Qian; Alfredo Selim; Lewis Kazis; Leonard Pogach; Anushua Sinha
Journal:  Qual Life Res       Date:  2012-03-06       Impact factor: 4.147

3.  Predictors of health utility among 60-day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study.

Authors:  Kirsten L Johansen; Mark W Smith; Mark L Unruh; Andrew M Siroka; Theresa Z O'Connor; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

4.  Long-Term Effects of Frequent In-Center Hemodialysis.

Authors:  Glenn M Chertow; Nathan W Levin; Gerald J Beck; John T Daugirdas; Paul W Eggers; Alan S Kliger; Brett Larive; Michael V Rocco; Tom Greene
Journal:  J Am Soc Nephrol       Date:  2015-10-14       Impact factor: 10.121

5.  Association Between the Publication of the Initiating Dialysis Early and Late Trial and the Timing of Dialysis Initiation in Canada.

Authors:  Thomas W Ferguson; Amit X Garg; Manish M Sood; Claudio Rigatto; Elaine Chau; Paul Komenda; David Naimark; Gihad E Nesrallah; Steven D Soroka; Monica Beaulieu; Ahsan Alam; S Joseph Kim; Stephanie Dixon; Braden Manns; Navdeep Tangri
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

6.  The costs and benefits of automatic estimated glomerular filtration rate reporting.

Authors:  Julia R den Hartog; Peter P Reese; Borut Cizman; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 8.237

7.  Physician visits and 30-day hospital readmissions in patients receiving hemodialysis.

Authors:  Kevin F Erickson; Wolfgang C Winkelmayer; Glenn M Chertow; Jay Bhattacharya
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

8.  Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Authors:  Kevin F Erickson; Glenn M Chertow; Jeremy D Goldhaber-Fiebert
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

9.  Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease.

Authors:  Mark M Mitsnefes; Thelma S Kathman; Jaya Mishra; Janis Kartal; Philip R Khoury; Thomas L Nickolas; Jonathan Barasch; Prasad Devarajan
Journal:  Pediatr Nephrol       Date:  2006-10-27       Impact factor: 3.714

10.  A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients.

Authors:  Eduardo Lacson; Jianglin Xu; Shu-Fang Lin; Sandie Guerra Dean; J Michael Lazarus; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.